Novo Nordisk cuts price of weight-loss drug for uninsured

Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss
Weight Loss Drug Will Be Offered for $499 a Month for Some Patients
Wegovy price cut: Novo Nordisk cuts the price of the weight-loss drug for the uninsured
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating
US judge denies injunction, restricting copies of Lilly weight-loss drug
A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and diabetes drugs Zepbound and Mounjaro in the United States.